Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.33 |
| ▸ | CPT1A | P50416 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30749335 | 0.91 | MEN1 (0.33) | USP2MAPK1CPT1AMAPTALDH1A1 | |
| SCHEMBL27224146 | 0.88 | CPT1A (0.34) | CPT1AALDH1A1 | |
| SCHEMBL27231643 | 0.88 | CPT1A (0.34) | CPT1AALDH1A1 | |
| SCHEMBL30749267 | 0.82 | MPO (0.38) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL30749309 | 0.80 | ALDH1A1 (0.37) | MAPK1CPT1AMAPTALDH1A1PKM | |
| SCHEMBL27223562 | 0.80 | ALDH1A1 (0.35) | USP2MAPK1MAPTALDH1A1ALOX15 | |
| SCHEMBL27224167 | 0.77 | F2 (0.37) | CPT1AALDH1A1 | |
| SCHEMBL30749302 | 0.73 | ALOX15 (0.34) | USP2MAPK1MAPTALDH1A1ALOX15 | |
| SCHEMBL27223632 | 0.73 | ALOX15 (0.34) | USP2MAPK1MAPTALDH1A1ALOX15 | |
| SCHEMBL30749253 | 0.72 | MPO (0.40) | MAPTALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240166642-A1 | INHIBITORS OF MYELOPEROXIDASE | ASTRAZENECA AB (SE) | 2024-05-23 | — | — | US | disclosed |
| WO-2024038131-A1 | INHIBITORS OF MYELOPEROXIDASE | ASTRAZENECA AB (SE) | 2024-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240166642-A1 | INHIBITORS OF MYELOPEROXIDASE | MPO, XDH, EPX | USP2 1448/4885MAPK1 2124/4885CPT1A 705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.